These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2721547)

  • 21. No. 302, a newly synthesized [pGlu4,Cyt6]AVP(4-9) analogue, prevents the disruption of avoidance behavior.
    Hirate K; Hirano M; Nakajima Y; Hiyama A; Maeda O; Asakura W
    Behav Brain Res; 1997 Feb; 83(1-2):205-8. PubMed ID: 9062685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central effects of vasopressin and 1-desamino-8-D-arginine vasopressin (DDAVP) on interleukin-1 fever in the rat.
    Naylor AM; Gubitz GJ; Dinarello CA; Veale WL
    Brain Res; 1987 Jan; 401(1):173-7. PubMed ID: 2949799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence supporting a role for endogenous vasopressin in fever suppression in the rat.
    Cooper KE; Naylor AM; Veale WL
    J Physiol; 1987 Jun; 387():163-72. PubMed ID: 3498828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of V1/V2-receptor antagonism on renal function and response to vasopressin in conscious dogs.
    Rose CE; Rose KY; Kinter LB
    Am J Physiol; 1991 Feb; 260(2 Pt 2):F273-82. PubMed ID: 1825453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopressin-induced antipyresis in the medial amygdaloid nucleus of conscious rats.
    Federico P; Veale WL; Pittman QJ
    Am J Physiol; 1992 May; 262(5 Pt 2):R901-8. PubMed ID: 1534208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specificity of aversive stimulus properties of vasopressin.
    Bluthé RM; Dantzer R; Mormède P; Le Moal M
    Psychopharmacology (Berl); 1985; 87(2):238-41. PubMed ID: 3931152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memory effects of arginine vasopressin (AVP) and [7-9] fragment of its peptide chain in rats.
    Klimkiewicz T
    Acta Neurobiol Exp (Wars); 2001; 61(4):267-76. PubMed ID: 11905148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors.
    Chan WY; Wo NC; Stoev S; Cheng LL; Manning M
    Br J Pharmacol; 1998 Oct; 125(4):803-11. PubMed ID: 9831918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of vasopressin antagonist d(CH2)5Tyr(Et)VAVP on plasma arginine vasopressin level after osmotic stimulus.
    László FA; Laczi F; Janáky T; Baláspiri L
    Endocr Regul; 1991 Sep; 25(3):181-3. PubMed ID: 1764609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain vasopressin and sodium appetite.
    Flynn FW; Kirchner TR; Clinton ME
    Am J Physiol Regul Integr Comp Physiol; 2002 Apr; 282(4):R1236-44. PubMed ID: 11893630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central target for the behavioural effects of vasopressin neuropeptides.
    de Wied D; Gaffori O; van Ree JM; de Jong W
    Nature; 1984 Mar 15-21; 308(5956):276-8. PubMed ID: 6322010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the influence of vasopressin neuropeptides on social recognition of rats.
    Sekiguchi R; Wolterink G; van Ree JM
    Eur Neuropsychopharmacol; 1991 May; 1(2):123-6. PubMed ID: 1821701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasopressin and oxytocin. Their presence in the central nervous system and their functional significance in brain processes related to behaviour and memory.
    van Wimersma Greidanus TB; Burbach JP; Veldhuis HD
    Acta Endocrinol Suppl (Copenh); 1986; 276():85-94. PubMed ID: 3463110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central injections of arginine vasopressin prolong extinction of active avoidance.
    Koob GF; Dantzer R; Bluthé RM; Lebrun C; Bloom FE; Le Moal M
    Peptides; 1986; 7(2):213-8. PubMed ID: 3737445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of arginine-vasopressin fragment 4-9 on rodent cholinergic systems.
    Tanabe S; Shishido Y; Nakayama Y; Furushiro M; Hashimoto S; Terasaki T; Tsujimoto G; Yokokura T
    Pharmacol Biochem Behav; 1999 Aug; 63(4):549-53. PubMed ID: 10462183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium deficiency enhances the behavioral responses to centrally administered vasopressin in rats.
    Flynn FW
    Peptides; 2002 Aug; 23(8):1427-32. PubMed ID: 12182943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood pressure and heart rate effect of a vasopressin antagonist in conscious normotensive rats pretreated with exogenous vasopressin.
    Waeber B; Nussberger J; Brunner HR
    Eur J Pharmacol; 1983 Jul; 91(1):135-7. PubMed ID: 6688586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of dPTyr(Me)AVP, a vasopressin antagonist, upon foot shock analgesia.
    Kordower JH; Bodnar RJ
    Int J Neurosci; 1985 Dec; 28(3-4):269-78. PubMed ID: 3005187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pinealectomy blocks modulation of active avoidance by central vasopressin application in rats.
    Appenrodt E; Schwarzberg H
    Peptides; 2003 Jan; 24(1):129-36. PubMed ID: 12576094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed effect of the vasopressin metabolite VP4-8 on the social memory of sexually naive male rats.
    Reijmers LG; Baars AM; Burbach JP; Spruijt BM; van Ree JM
    Psychopharmacology (Berl); 2001 Apr; 154(4):408-14. PubMed ID: 11349395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.